July 27, 2021
Recently, Micomme has associated Polish and Peruvian partners to accomplished the government centralized purchasing of 1,600 and 1,500 unites HFNC respectively. Both purchasements are strategic material reserves of the local government. The global pandemic is still raging, and the safety of people’s lives is the primary goal pursued by the government. The projects also reflect the foresight and determination of the local government. Both two projects have all been delivered in June 2021.
As the leading non-invasive respiratory therapy company in China, Micomme Medical has launched the first transnasal High-Flow Nasal Cannula Oxygen Therapy Device (hereinafter referred to as HFNC) OH-70C since 2017 in China. At the beginning of the pandemic outbreak, Micomme Medical responded quickly during the traditional Chinese Spring Festival. All employees returned to work from holiday, the production line was fully activated, and more than 5,000 units HFNC were sent to Wuhan immediately. In 2020, Micomme has achieved more than 10,000 HFNC installations worldwide (China not included), and helps countries around the world fight against COVID-19 with a production capacity of 500 units per day.
The transnasal High-Flow Nasal Cannula Oxygen Therapy Device is the machine recommended by WHO and related international guidelines for the treatment of patients with COVID-19. It aims to quickly increase the patient’s oxygen saturation (SpO2) and improve the symptoms of hypoxia in patients by providing a high-flow air-oxygen mixed gas to patients with a constant temperature, humidity and a constant oxygen concentration. As the first HFNC manufacturer in China, Micomme has won the market's recognition with its excellent product quality and brilliant product performance. In the battle against COVID-19, Micomme fulfills the commitment as the leading company !
For more details, please contact: firstname.lastname@example.org